Inflammatory Bowel Disease (IBD) refers to a set of diseases that cause chronic inflammation of the small and/or large intestines. The global prevalence of IBD exceeds 3 million cases, approximately 1.8 million of which are in the United States. Roughly 45% of cases are defined as Crohn’s disease and 55% are ulcerative colitis (UC). Crohn’s and UC can occur at any age, but diagnoses are most frequent between the ages of 15 and 35.
Artizan scientists have deciphered a mechanism by which certain bacteria infiltrate and disrupt the interior lining of the intestines. By blocking this mechanism, Artizan’s therapeutic candidates may protect and restore gut barrier integrity. Artizan currently has several drug targets under investigation for which we are developing small molecule and antibody therapeutics.
For more information about IBD, please visit the Crohn’s & Colitis Foundation.